Summary by Moomoo AI
On February 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, executed a sale of company stock. The transaction involved the disposal of 20,000 common shares at prices ranging from $79.9359 to $81.6645 per share, resulting in a total market value of $1,607,177.46. Prior to the sale, Kulkarni acquired the same number of shares through the exercise of derivative securities at a price of $19.12 per share. Following the transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an entity not directly tied to the reported transactions.